NanoViricides, Inc. (NNVC)
1.44
-0.07
(-4.64%)
USD |
NYAM |
Oct 22, 15:39
NanoViricides EPS Diluted (Quarterly) : -0.0996 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0996 |
| March 31, 2026 | -0.0921 |
| December 31, 2025 | -0.1119 |
| September 30, 2025 | -0.1045 |
| June 30, 2025 | -0.1269 |
| March 31, 2025 | -0.1383 |
| December 31, 2024 | -0.1391 |
| September 30, 2024 | -0.228 |
| June 30, 2024 | -0.1932 |
| March 31, 2024 | -0.1574 |
| December 31, 2023 | -0.1801 |
| September 30, 2023 | -0.168 |
| June 30, 2023 | -0.3052 |
| March 31, 2023 | -0.1463 |
| December 31, 2022 | -0.1503 |
| September 30, 2022 | -0.1355 |
| June 30, 2022 | -0.1536 |
| March 31, 2022 | -0.1553 |
| December 31, 2021 | -0.1667 |
| September 30, 2021 | -0.2269 |
| June 30, 2021 | -0.18 |
| March 31, 2021 | -0.1925 |
| December 31, 2020 | -0.2185 |
| September 30, 2020 | -0.2204 |
| June 30, 2020 | -0.2064 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.240 |
| December 31, 2019 | -0.5002 |
| September 30, 2019 | -0.406 |
| June 30, 2019 | -0.5758 |
| March 31, 2019 | -0.5948 |
| December 31, 2018 | -0.643 |
| September 30, 2018 | -0.5324 |
| June 30, 2018 | -0.40 |
| March 31, 2018 | -0.60 |
| December 31, 2017 | -0.80 |
| September 30, 2017 | -0.60 |
| June 30, 2017 | -0.80 |
| March 31, 2017 | -1.00 |
| December 31, 2016 | -0.60 |
| September 30, 2016 | -1.00 |
| June 30, 2016 | -0.60 |
| March 31, 2016 | -1.80 |
| December 31, 2015 | -1.00 |
| September 30, 2015 | -0.40 |
| June 30, 2015 | -0.4384 |
| March 31, 2015 | -0.40 |
| December 31, 2014 | -0.6352 |
| September 30, 2014 | -0.08 |
| June 30, 2014 | -1.956 |
| March 31, 2014 | -0.40 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.223M |
| Total Expenses (Quarterly) | 2.223M |
| Enterprise Value | 31.95M |
| Earnings Yield | -28.34% |
| Normalized Earnings Yield | -28.34 |